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A B S T R A C T   
Background: Delirium is a common neuropsychiatric disorder associated with prolonged hospital stays, and 
increased morbidity and mortality. Diagnosis is frequently missed due to varying disease presentation and lack of 
standardized testing. We examined biomarkers as diagnostic or prognostic indicators of delirium, and provide a 
rational basis for future studies. 
Method: Systematic review of literature published between Jan 2000 and June 2019. Searches included: PubMed; 
Web of Science; CINAHL; EMBASE; COCHRANE and Medline. Additional studies were identified by searching 
bibliographies of eligible articles. 
Results: 2082 relevant papers were identified from all sources. Seventy-three met the inclusion criteria, all of 
which were observational. These assessed a range of fourteen biomarkers. All papers included were in the English 
language. Assessment methods varied between studies, including: DSM criteria; Confusion Assessment Method 
(CAM) or CAM-Intensive Care Unit (ICU). Delirium severity was measured using the Delirium Rating Scale (DRS). 
Delirium was secondary to post-operative dysfunction or acute medical conditions. 
Conclusion: Evidence does not currently support the use of any one biomarker. However, certain markers were 
associated with promising results and may warrant evaluation in future studies. Heterogeneity across study 
methods may have contributed to inconclusive results, and more clarity may arise from standardization of 
methods of clinical assessment. Adjusting for comorbidities may improve understanding of the pathophysiology 
of delirium, in particular the role of confounders such as inflammation, cognitive disorders and surgical trauma. 
Future research may also benefit from inclusion of other diagnostic modalities such as EEG as well as analysis of 
genetic or epigenetic factors.   
1. Background 
Delirium is a serious neuropsychiatric condition affecting >15% of 
hospital inpatients [1]. It has been defined as a transient reversible 
syndrome that is acute and fluctuating, occurring in the setting of a 
medical condition. It is associated with increased morbidity, mortality 
and cognitive decline and contributes to longer hospital stays and 
increased healthcare costs [2,3]. Despite its importance, diagnosis re-
mains challenging, with more than 50% of delirium cases estimated as 
undiagnosed [4–6] leading to decreased quality of care and poor patient 
outcomes. 
Several factors contribute to this difficulty in diagnosis, including: 
lack of clarity on how diagnostic criteria should be tested; variance in 
presentation of delirium subtypes; and masking by comorbidities [7]. 
Additionally, the underlying pathophysiology of delirium remains 
poorly understood. The three primary hypotheses include: (1) distur-
bances in neurotransmitter pathways; (2) activation of pro- 
inflammatory cytokines resulting in breakdown of the blood brain 
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barrier; or (3) disruption of the hypothalamic-pituitary-axis in reaction 
to acute stress [8]. 
Diagnosis currently relies on the Diagnosis and Statistics Manual 5th 
Edition (DSM-V). According to these criteria, delirium is characterized 
by acute onset disturbances in cognition, attention and awareness, 
fluctuating in severity throughout the day [9]. More specifically, dis-
turbances in consciousness may manifest as reduced clarity of awareness 
of the environment, with reduced ability to focus or sustain attention. Its 
association with pre-existing, established or evolving neurocognitive 
disorders and perceptual disturbances and psychomotor behavioural 
changes are not well understood [10]. The DSM-V does not outline a 
specific clinical testing method. 
The identification of biomarkers associated with delirium may pro-
vide insight into its elusive pathophysiology and aid in prediction, 
diagnosis and management. Biomarkers are biological or molecular 
traces that may indicate the presence or severity of disease [11]. They 
are categorized into three patterns [11]: (1) Risk markers, the presence 
of which indicates risk of a particular disease; (2) disease markers, 
correlating with the onset and recovery of disease; and (3) end-products 
that indicate disease resolution. 
While biomarkers have been identified as associated with delirium, 
studies present conflicting results. For this reason, no biomarker(s) has 
been determined as specific to delirium. To date, there has been only one 
systematic review of molecular signals in delirium, which was limited to 
cerebrospinal fluid (CSF) markers [12]. Therefore, in performing this 
systematic review, we attempted to identify all available accessible 
literature examining biomarkers associated with delirium, and to criti-
cally appraise these studies in the context of current hypotheses of 
delirium pathophysiology. The objective was to assess the diagnostic 
and prognostic value of biomarkers of delirium and, if appropriate, to 
suggest a rational basis for future studies. 
2. Methods 
2.1. Systematic review tool 
This review adheres to PRISMA (http://www.prisma-statement.or 
g/) and Meta-analysis of Observational Studies in Epidemiology guide-
lines [13]. 
2.2. Study identification 
An electronic search without restrictions (other than published in the 
English language) was performed for literature published between Jan 
2000 and June 2019 that investigated biomarkers in delirium settings. 
Studies were identified from MEDLINE (beginning 1966), EMBASE 
(beginning 1974), CINAHL (beginning 1980), Web of Science (begin-
ning 1980), and the COCHRANE databases. Primary key words 
included: “delirium” and “marker” used in combination with additional 
key words including: “biomarker”, “biological”, “biologic”, “marker”, 
“delirium”, “serum”, “plasma”, “genetic” and “protein”. Boolean oper-
ators were used to combine search terms above. Truncation and wild-
cards were applied to capture as many results as possible. Additional 
studies were identified by searching bibliographies in relevant articles 
identified in the searches. To avoid bias, results were based on analysis 
by SSD, CCC, SG and SK. Variations in interpretation were reviewed, and 
any disputes were resolved, by CPD. Final analysis was reviewed by JCC, 
GG, DM and CPD. 
2.3. Selection criteria 
Inclusion criteria were: (1) studies that investigated the relationship 
between biomarker(s) and delirium;(2) studies in which delirium was 
Records identified through database searching 
(2082)






 Duplicate records (123)
 Irrelevant papers(1727)
 Case reports, Reviews, Delirium 
Tremens (147)




 Short abstracts (7)
 Letters to editors (2)
 Post-mortem study (1)
 No diagnosis of delirium made (9)
 Delirium Tremens (2)
 Mixed group with SLE (1)Studies included in systematic 
review
(73) 
Fig. 1. PRISMA flow diagram of the process of (and reasons for) including and excluding studies.  
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assessed using a validated assessment tool; (3) any study methodology 
leading to publication within the topic of interest;and (4) full-text of 
original research papers. 
Exclusion criteria were: (1) case reports, abstracts, letters and edi-
torials; (2) studies before January 2000; (3) studies involving delirium 
tremens; (4) studies not written in the English language; or (5) animal 
model studies. 
For the purposes of this review, pre-existing cognitive impairment is 
treated as undiagnosed dementia and is therefore not included as 
delirium. Additionally, this study makes a distinction between delirium- 
only studies, which will be referred to as “pure delirium”, and delirium 
with comorbidities. 
2.4. Data extraction 
Titles and abstracts of searched articles were screened for relevance. 
Data extracted included: (1) study design; (2) objectives; (3) markers; 
(4) incidence or prevalence of delirium; (5) etiology of delirium;(6) 
delirium assessment tool; (7) timing of delirium assessment; (8) method 
of biomarker quantification; (9) timing of marker assessment; (10) 
sample size; (11) median/mean age of participants;(12) number of 
controls and cases; (13) assessment of variables/confounders; (14) 
outcome(s); (15) effect of variables/confounders; and (16) study 
limitations. 
3. Results 
A total of 2082 studies were identified from database searches of 
PubMed, CINAHL, EMBASE, COCHRANE and Medline. An additional 
ten articles were retrieved following review of bibliographies of eligible 
articles. Subsequent to review of titles and abstracts, 1997 records were 
discarded and the full manuscripts of 95 studies were examined in detail. 
Of the 95 papers, 22 papers were discarded as ineligible (Fig. 1). 
Thus, 73 studies were included for full appraisal, all of which were 
observational in design. Delirium was assessed using the DSM criteria, 
Confusion Assessment Method (CAM) or CAM-Intensive Care Unit (ICU) 
for patients in the ICU. Delirium severity was measured using the 
Delirium Rating Scale (DRS). Across the 73 included studies, 14 markers 
of delirium were examined (Supplementary Table 1). Studies included 
markers (singly or combinations) from cerebrospinal fluid (CSF), serum, 
or plasma. 
3.1. Study characteristics 
There was significant diversity between the studies included, such as 
patient populations and settings, study design, and biomarker(s) 
examined. With regard to setting, participants included patients from 
either medical or surgical setting. Surgical patients varied from cardiac 
to orthopaedic. Medical patients were either acutely or critically ill. The 
notable Flacker et al. study [14], which examined febrile patients in a 
long-term care facility was included in the medical setting category. 
Study designs included either or both cross-sectional and longitudinal 
data. Within studies, delirium and marker(s) were assessed at single or 
multiple time points. 
Study outcomes included statistically significant changes in 
biomarker levels “pre-delirium”, “during-delirium”, and/or “post- 
delirium” compared to control groups with no delirium. The most 
frequently studied marker was Interleukin-6 (IL-6) (n = 23) followed by 
C-reactive protein (CRP) (n = 17), cortisol (n = 11), S–100B (n = 10), 
IGF-1 (n = 10) and TNF-alpha (n = 9). Thirty-three studies investigated 
markers associated with delirium-only and 40 studies investigated 
markers in patients with other comorbidities, including depression and/ 
or pre-existing cognitive dysfunction/dementia. 
Amongst the delirium-only studies, authors either excluded patients 
with comorbidities or did not evaluate neurocognition to determine the 
presence or absence of comorbidities. Studies including additional 
comorbidities did not adjust consistently for the presence of these con-
founders. As noted below, pre-existing cognitive impairment is treated 
as dementia in this study. With regard to individual biomarkers, each is 
discussed briefly below, with considerable detail provided in Supple-
mentary Tables dedicated to each separately. Each Table provides 
country of origin, clinical setting, sample type, number of samples uti-
lized, number of control samples versus delirium cases, biomarkers 
assessed and study findings. Therefore, the following text details 
important summary details only. 
Table 1 provides a list of all identified studies demonstrating an as-
sociation, clarifying whether positive or negative, between delirium and 
specific biomarkers. A summary of all associations found is provided in 
Fig. 2. 
3.2. Serum anticholinergic activity (SAA) 
SAA was investigated as a marker of delirium in six studies (Sup-
plementary Table 2). There were mixed results as three of the six papers 
demonstrated no association between SAA and delirium. SAA was 
studied alone in three papers [15–17], alongside EEG in two [18,19] and 
alongside other inflammatory markers in one paper [20]. It is worth 
noting that of the 73 studies eligible studies in this review, only three 
involved assessment of EEG [18,19,21]. There was no difference in the 
proportion of studies showing an association between those studies 
examining delirium alone and those that examined delirium with 
comorbidities. Delirium with comorbidities was the more broadly 
studied form, featuring in four of six studies. Similarly, studies in a 
surgical setting were more common in this group, involving four of six 
studies. Of note, the three studies [15,17,22] that found an association 
were performed in a surgical setting, and all three found that lower 
levels of cholinesterases in the pre-operative period were associated 
with incidences of delirium in the post-operative period. A fourth study, 
also involving surgical patients, by contrast found an increase in SAA 
activity in delirious patients, but the association lost significance after 
adjusting for pre-existing cognitive dysfunction [16]. All studies utilized 
serum samples, and used either a cholinesterase assay [17] [22], radi-
oreceptor assay [18] [19] or an immunoassay [15] including radioim-
munoassays [16] in their analyses. 
3.2.1. Amino acids as a marker of delirium 
Three studies assessed the value of homovanillic acid (HVA) as a 
marker of delirium, two of which adjusted for comorbidities including 
cognitive impairment [23] or cognitive impairment and depression 
[24]. Only Ramirez et al. [25] assessed an amino acid in the setting of 
pure delirium. HVA was either assessed alone [25], as part of a study 
involving neuropsychiatric patients, or as part of a suite of other amino 
acids in either medical [23] or surgical [24] patients. Two of three 
studies measuring HVA reported no association between this marker and 
delirium [23–25] while the third study [24] demonstrated elevated 
levels of HVA in pre-operative and post-operative surgical patients with 
delirium alongside elevated neopterin [24] as well as, in post-operative 
patients, phenylalanine to LNAA ratio and citrulline. The most common 
sampling method for HVA was serum, which was employed in two 
studies [23 24] while, in the third study, CSF samples were analyzed 
using HPLC. 
All other amino acids were assessed as part of a group of two or more 
biomarkers and were assessed in delirium adjusting for comorbidities 
(Supplementary Table 3). Amongst these, tryptophan was the most 
common, featuring in six studies and with ambiguous results. Two of the 
six studies demonstrated a significant association between elevated 
levels of tryptophan and post-operative delirium [26 27], while three 
studies found significantly lower levels of tryptophan in delirious pa-
tients [24 28 29]. One study involving orthopaedic surgery patients 
reported no association [30] and had adjusted for cognitive impairment. 
This, in particular, is notable as orthopaedic surgery patients are 
sometimes affected by reduced oxygen saturation due to undiagnosed 
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pulmonary emboli (especially associated with hip fractures and, 
frequently, older patients). All except one of the studies [27] analyzing 
tryptophan were performed in surgical settings and most used serum 
samples only, with exception of two that also included CSF [26 27]. 
Four studies assessed the tryptophan/LNAA ratio, all of which found 
significant association between low levels of the tryptophan:LNAA ratios 
and delirium compared to non-delirious controls [23,24,27,28]. These 
included delirium in both surgical [24,28,30] and medical [23,27] set-
tings. Comorbidities noted in the studies included dementia and 
depression. One study did not have significant findings after controlling 
for Mini Mental State Exam (MMSE) [23], one did not adjust for vari-
ables [28], and two remained statistically significant having controlled 
for variables[24,27]. Three studies demonstrated an association 
between elevated phenylalanine:LNAA ratio and delirium. These 
investigated medical [14] and post-operative delirium [24,28] using 
serum samples. 
3.3. Melatonin 
Three papers explored a link between melatonin and delirium, and 
found significant associations (Supplementary Table 4). The studies 
examining pure delirium, however, presented conflicting results. One 
described a positive association between melatonin and delirium in post- 
operative patients [31], while a second reported an association between 
decreased melatonin levels post-operatively and post-operative delirium 
[32]. Of note, the results of these two studies were hampered by low 
Table 1 
Identified studies demonstrating associations between delirium and specific biomarkers.  
Authors (Year) (Origin) [Ref] Markers with positive association Markers with negative association 
Adamis et al. (2007) (Ireland) [53] – IGF-1, recovery associated with lack of APOE allele 
Adamis et al. (2009) (Ireland) [52] – IGF-1, IL-1ra 
Al Tmimi et al. (2016) (Belgium) [71] S100B – 
Alexander et al. (2014) (USA) [47] IL-6, APOE4 allele – 
Avila-Funes et al. (2015) (Mexico) [86] Estradiol (E2) – 
Baranyi et al. (2014) (Germany) [57] SIL-2R – 
Cape et al. (2014) (UK) [56] IL-1B, IL-RA – 
Capri et al. (2014) (Italy) [41] IL-6 IL-2 
Cerejeira et al. (2011) (Portugal) [17] – Cholinesterase 
Cerejeira et al. (2012) (Portugal) [22] IL-8 Acetylecholinesterase, butylcholinesterase 
Cerejeira et al. (2013) (Portugal) [20] Cortisol – 
Colkesen et al. (2013) (Turkey) [84] Cortisol – 
De Jonghe et al. (2012) (The Netherlands) [30] Kynurenine: Tryptophan ratio – 
De Rooij et al. (2007) (The Netherlands) [50] IL-6, IL-8 – 
Dillon et al. (2017) (USA) [60] CRP – 
Egberts et al. (2015) (The Netherlands) [23] Phenylalanine: LNAA ratio Tryptophan:LNAA ratio, arginine 
Egberts et al. (2015) (The Netherlands) [46] Neopterin, IL-6 IGF-1 
Erikson et al. (2019) (Finland) [43] IL-6, *correlation between S100B and IL-6 – 
Flacker et al. (2000) (USA) [14] Phenylalanine: LNAA ratio – 
Girard et al. (2012) (USA) [59] STNFR1 – 
Hall et al. (2013) (UK) [72] S100B – 
Hirsch et al. (2016) (USA) [36] IL-6, RAGE, IL-5 (postop), IL-8, MCP-1 IFN-a, IL-4, IL-5 (preop), IGN-gamma, IL-12 
Hughes et al. (2016) (USA) [75] S100B (fewer delirium free days) – 
Jorge-Ripper et al. (2016) (Spain) [49] TNF-alpha – 
Kazmierski et al. (2013)(Poland) [83] Corstisol – 
Kazmierski et al. (2014)(Poland) [58] IL-2, TNF-alpha – 
Knaak et al. (2019) (Germany) [65] CRP – 
Lee et al. (2011) (Korea) [61] CRP – 
Leung et al. (2007) (USA) [79] APOE-4 allele – 
Liu et al. (2013) (Korea) [35] IL-6 – 
McManus et al. (2009) (UK) [63] CRP – 
Miao et al. (2018) (China) [40] Neopterin, CRP, IL-6, IGF-1 – 
Mu et al. (2010) (China) [82] Cortisol – 
Osse et al. (2012) (The Netherlands) [24] Homovanillic acid, phenylalanine:LNAA ratio, citrulline Tryptophan:LNAA ratio, methionine, tryptophan, serine 
Pandharipande et al. (2009) (USA) [27] Tryptophan Tryptophan:LNAA ratio, Tyrosine:LNAA ratio 
Pearson et al. (2010) (UK) [81] Cortisol – 
Pfister et al. (2008) (Switzerland) [48] CRP, S100B,cortisol – 
Piotrowicz et al. (2015) (Poland) [33] Melatonin – 
Plaschke et al. (2010) (Germany) [21] IL-6, cortisol Mean BIS index 
Pol et al. (2014) (The Netherlands) [67] CRP – 
Ritchie et al. (2014) (UK) [62] CRP – 
Ritter et al. (2014) (Brazil) [55] STNFR1/2, adiponectin, IL-1B – 
Robinson et al. (2008) (USA) [29] – Tryptophan 
Shen et al. (2016) (China) [68] – IGF-1 
Shigeta et al. (2001) (Japan) [31] Melatonin – 
Sun et al. (2016) (China) [38] IL-6, CRP, procalcitonin, cortisol – 
Tsuruta et al. (2010) (Japan) [64] CRP – 
Van der Boogaard et al. (2011) (The Netherlands) [54] IL-8, cortisol – 
Van der Mast (2000) (The Netherlands) [28] Phenylalanine: LNAA ratio Tryptophan, Tryptophan:LNAA ratio 
Van Munster et al. (2008) (The Netherlands) [42] Il-6, Il-8 – 
Van Munster et al. (2010) (The Netherlands) [34] S100B, IL-6 – 
Vasunilashorn et al. (2015) (USA) [39] IL-6, I-2, TNF-alpha – 
Watne et al. (2016) (Norway) [26] Tryptophan, tyrosine, methionine, phenylalanine, HIAA – 
Westhoff et al. (2013) (The Netherlands) [37] IL-6 (serum) IL-6 (CSF), IL-RA, Flt-3 l 
Wilson et al. (2005) (UK) [69] – IGF-1 
Yoshitaka et al. (2013) (Japan) [32] – Melatonin 
Zhang et al. (2014) (China) [66] CRP – 
Zhao et al. (2019) (China) [15] – Acetlycholinesterase, butylcholinesterase  
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participant numbers. A third study involving medical patients reported a 
positive association between elevated levels of melatonin and delirium, 
accounting for dementia as a comorbidity [33]. The findings indicated a 
significant association irrespective of dementia state during acute 
delirium and post-resolution in non-demented patients. All three studies 
examining melatonin used serum samples and radio-immunoassays. 
3.4. Interleukin-6 (IL-6) 
IL-6 was the most studied biomarker (Supplementary Table 5). It 
featured in 23 studies with 14 of these demonstrating a significant as-
sociation between elevated IL-6 and occurrence of delirium, while the 
remaining nine found no significant association. Van Munster et al. [34] 
initially showed an association between IL-6 and delirium, but this lost 
significance following adjustment for pre-existing cognitive impairment. 
In all but one study [35], IL-6 was analyzed alongside a panel other 
inflammatory markers. 
Surgical settings accounted for 15 of the 23 studies, and surgical 
studies accounted for 10 of the 14 studies which showed an association 
between IL-6 and delirium. Notably, there was no clear time pattern of 
raised IL-6 relative to surgery. This marker was shown to be elevated in 
the pre-operative period[21,36–38], the post-operative period [39,40] 
or both[22,35,41] in patients who developed delirium although one 
surgical study noted specifically that the markers were higher in patients 
during delirium [42]. While results relating to IL-6 alone were generally 
significant, some studies [20,22,36,43] reported a correlation between 
IL-6 and other inflammatory markers, and many reported trends in IL-6 
alongside other inflammatory markers. Sun et al. [38], for example, 
reported a general increase in all biomarkers in the post-operative 
delirium group, while Rudolph et al. [44] observed a difference be-
tween chemokines but not cytokines (including IL-6) in post-operative 
surgical patients. The significance of surgery-related trauma and its in-
fluence on inflammatory markers is extrapolated in the discussion sec-
tion below. 
Twelve of the 23 studies adjusted for comorbidities with cognitive 
impairment as a comorbidity common to all studies, except one that 
adjusted for depression [22]. All 23 studies in this group used serum 
samples while two [36 45] also included CSF. Analysis involved ELISA, 
multiplex assay, cytometric bead immunoassay, or CLIA immunoturbi-
dimetric assay. 
3.5. Interleukin-8 (IL-8) 
The potential involvement of IL-8 in delirium was investigated in 
seven studies (Supplementary Table 6). Six [22,34,36,42,50,54] re-
ported positive associations between elevated IL-8 and delirium, while 
one measured IL-8 levels below the detection limit, precluding mean-
ingful analysis [41]. 
All seven studies assessed IL-8 alongside other inflammatory 
markers. While only one study assessed a correlation [20], trends of IL-8 
in delirium in some studies matched those of other inflammatory 
markers such as IL-6 [36]. Van Munster et al. [42] found IL-8 to be 
highest in patients with delirium, with the greatest levels occurring in 
the days directly preceding delirium onset and remaining high during 
delirium, while Cerejeira et al. [20,22] described a small increase in IL-8 
both pre-operatively and post-operatively in delirious patients [22]. One 
study detailed a significant elevation of IL-8 in medically delirious pa-
tients with inflammation, defined as a positive blood culture or presence 
of two or more SIRS criteria markers, compared to non-inflamed delir-
ious patients [54]. This finding remained significant even after adjusting 
for multiple clinical variables. 
Medical settings accounted for only two of these seven studies 
[50,54]. Both reported a positive association. Amongst the surgical 
studies, four of five [20,22,36,42] involved orthopaedic surgery pa-
tients, while one involved cardiac surgery patients [41] and three of five 
showed a positive association, with one returning non-significant data 
[41]. 
It was relatively common amongst studies assessing for IL-8 to adjust 
for comorbidities, which five of the seven studies did. Comorbidities 
included; depression [22], cognitive impairment [42,50], depression 
and dementia [22] and depression with neurocognitive disorder [36]. 
Four of these five found significant associations, while one [20] found no 
association between IL-8 and post-operative delirium after adjusting for 
comorbidities. 
All assessed serum samples albeit one [36] also assessed for IL-8 in 















* Although graph indicates a high proporon of associaons found, these findings were 
contradictory. Associaons were with both high and low levels of these markers.
Data insufficient/ not significant
No associaon comorbidies
No associaon pure delirium
Associaon comorbidies
Associaon pure delirium
Fig. 2. Graphic summary of studies showing an association, lack of association, or insufficient data.  
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System 200, cytometric-bead immunoassay, luminex assay. The study 
assessing both serum and CSF used ELISA [36]. 
3.6. Interleukin-1 (IL-1) 
Five publications concentrated on IL-1 as a marker of delirium 
(Supplementary Table 7). Two cohort studies showed a significant as-
sociation between elevated levels of IL-1 and delirium, with two studies 
finding no association and one showing varied results depending on the 
type of IL-1 assessed. In all five studies, IL-1 was assessed as one of a 
number of inflammatory markers. 
There was no clear trend noted according to study setting. One of two 
studies involving medical patients showed an association, while one of 
three surgical studies showed an association. Similarly, there were no 
clear trends when assessing delirium or delirium with comorbidities. Of 
the two studies that explored the association of IL-1 and pure delirium, 
one showed an association [55]. This study was performed in a medical 
setting amongst septic and non-septic patients, demonstrating higher 
levels of IL-1B in delirious patients irrespective of the presence or 
absence of sepsis [55]. This finding remained significant after account-
ing for other variables. Of the three studies that adjusted for comor-
bidities, one found elevated IL-1B independent of dementia status [56]. 
Other comorbidities included depression [42]. 
Of note, many studies in this group assessed one of more variants of 
interleukin, including variants of IL-1. Capri et al., for example, pre-
sented divergent results for IL-1 and Il-6, measuring lower and higher 
respectively in patients with post-operative delirium [41]. Another 
study, performed in a medical setting, which adjusted for dementia 
found a positive association between low levels of the anti-inflammatory 
cytokine IL-1RA (interleukin 1 receptor antagonist) but not the pro- 
inflammatory IL1-alpha or IL-1beta and delirium [52]. 
All but one of the studies examining IL-1 analyzed serum samples 
only. The exception [56] also included CSF. Samples were analyzed 
using ELISA. 
3.7. Interleukin-2 (IL-2) 
IL-2 was the focus of four studies (Supplementary Table 8). Three of 
these found IL-2 to be a significant marker of delirium, with the final 
report failing to find significance. All four studies involved surgical 
patients who developed post-operative delirium, used serum samples 
and examined IL-2 as one of a group of inflammatory markers. 
Of the two studies examining the association between IL-2 and pure 
delirium, one found elevated IL-2 both pre- and post-operatively. 
However, this research group did not adjust for other clinical vari-
ables [39]. This result was contradicted by a second study, which 
confirmed significantly lower IL-2 levels in patients with post-operative 
delirium. However, significance was lost following adjustment for other 
variables [41]. Conflicting results were also identified between the two 
studies that adjusted for comorbidities. One of these, adjusted for 
depression, found significantly decreased sIL-2R in delirious patients in 
the first 24-h post-operatively followed by a sharp rise in this marker 
[57]. The second study determined elevated IL-2 post-operatively in 
patients with post-operative delirium compared to controls, indepen-
dent of other variables including dementia and depression [58]. Assay 
methods included CLIA and ELISA. 
3.8. C-reactive protein (CRP) 
Perhaps unsurprisingly, a relatively large number of researchers (17 
reports) focused on the relationship between CRP and delirium in 
medical and surgical settings (Supplementary Table 9). Eleven of the 
papers demonstrated a significant correlation. 
There were differences in the proportion of positive results amongst 
studies examining pure delirium compared with those examining 
delirium adjusted for comorbidities. Of the eight studies that examined 
the association with pure delirium, all of which assessed CRP as one of a 
panel of inflammatory markers, only one study found no association 
between levels of CRP and delirium [59], while seven demonstrated a 
positive association between raised levels of CRP and delirium 
[40,48,60–64]. By comparison, amongst the nine studies that investi-
gated the association between CRP and delirium, accounting for de-
mentia and/or depression, four studies, all of which recorded cognitive 
impairment as a comorbidity, detailed a positive association between 
elevated CRP and delirium [38,65–67] while the remainder stated no 
association between CRP and delirium [22,45,50,51,53]. The five 
studies that found no association reported cognitive dysfunction 
[45,50,53], as well as depression [22,51] as comorbidities. 
Of the studies showing a positive association, six were performed in a 
surgical setting, examining pre-and post-operative levels [40,60,61] 
accounting for six of the nine surgical studies assessing CRP and 
delirium. These found elevated CRP in either or both the pre- and post- 
operative period. Five positive studies were conducted in medical set-
tings with acutely ill patients [48,62–64,66], accounting for five of 
seven medical studies assessing CRP in delirium. One of these five 
studies adjusted for comorbidities [66]. Two of those in a medical 
setting did not evaluate the effect of covariates on the outcome [48,63]. 
Most of the studies assessing CRP analyzed serum samples, however two 
[38,51] assessed plasma samples and one [45] assessed CSF in addition 
to serum. 
3.9. Insulin-like growth factor − 1 
Ten papers described work to determine an association between 
levels of insulin-like growth factor-1 (IGF-1) and delirium (Supple-
mentary Table 10), three of which examined IGF-1 only [68–70] and 
seven which involved other inflammatory markers. 
Results were varied, with five studies [46,52,53,68,69] concluding 
that there was an association between low levels of IGF-1 and delirium, 
one finding association between elevated levels of IGF-1 and delirium 
[40], and four describing no association[20,51,56,70]. Two of the 
studies describing an association between elevated IGF-1 and delirium 
were conducted in a medical setting examining pure delirium[40,46], 
while a third paper showed increased levels of IGF-1 in plasma samples 
from patients with post-operative delirium [40]. In contrast, three 
studies in a medical setting, which investigated delirium with comor-
bidities, specifically cognitive impairment, determined an association 
between low IGF-1 and delirium [52,53,69]. All of the studies that 
identified a positive association in the setting of delirium adjusted for 
comorbidities were conducted in medical settings. Four studies were 
unable to correlate IGF-1 and delirium. Three of these were performed 
with post-operative surgical orthopaedic patients, and one was per-
formed in a medical setting [70]. All adjusted for comorbidities 
including dementia and pre-existing cognitive dysfunction. 
All papers examining IGF-1 used serum samples. One also included 
CFS [56]. Assays included immulite analyzer [46], ELISA 
[20,40,52,53,56,68] or immunoassay[51,69,70]. 
3.10. S–100B 
Ten studies investigated S–100B as a marker of delirium (Supple-
mentary Table 11), with four analyzing S–100B alone [71–74] and six 
including other inflammatory markers [34,43,48,49,75,76]. 
Six studies demonstrated a positive association between elevated 
levels of S–100B and delirium, while four found no association. 
Research showing a positive association was performed in both medical 
[43,48,75] and post-operative surgical [34,71,72] settings. There was 
no pattern in positive studies with regard to medical vs surgical setting, 
or between studies that adjusted for comorbidities vs those that 
measured pure delirium. Al Tmimi et al. [71], Hughes et al. [75] and 
Erikson et al. [43], all detected elevated levels of S–100B independent 
of covariates, although Pfister et al. [48] made no adjustments for 
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variables amongst the sample of sepsis-associated delirium patients. Of 
note, Hughes [75] demonstrated an additional association between 
increased S100B and the duration of delirium. The most common co-
morbidity in this group of studies was cognitive impairment, which was 
adjusted for in three studies [34,72,74], while neurocognitive disorder 
was adjusted for in one [73]. 
Four studies failed to determine association between S–100B and 
delirium; three in a medical setting[49,74,76] and one in a surgical 
setting [73]. Of these, Khan et al. [74] detected higher levels of S–100B 
in delirious patients, although the result was not significant. Beishuizen 
et al. [73] found that S100B was not associated with delirium, but was 
associated with cognitive decline or death in the first year following hip 
surgery. 
All studies measuring S–100B used serum samples, except for 
Erikson et al. [43] who used whole blood and Hall et al. [72] who uti-
lized CSF. ELISA and CLIA were used. 
3.11. Apolipoprotein- E (APO-E) 
APO-E in delirium was the focus of six studies (Supplementary 
Table 12), two of which [47,53] studied APO-E with other inflammatory 
markers. The others assessed APO-E alone. One demonstrated an asso-
ciation with occurrence of delirium while four did not. Five used serum 
sampling, while one [77] used whole blood. 
Two studies examined the association of APO-E on pure delirium, 
demonstrating no significant association with occurrence of delirium. 
One was performed in a surgical setting [78] and one in a medical 
setting [47]. Four studies investigated APO-E as a marker of delirium, 
adjusting for co-morbidities. One demonstrated a positive association 
between APO-E epsilon4 allele and delirium in non-cardiac post-oper-
ative patients with delirium [79], and three demonstrated no association 
in either surgical patients[77,80] or medical patients [53]. Of note, 
Adamis et al. [53] indicated an association between lack of serum APOE 
and delirium recovery in medical patients. 
These six studies account for the only direct analysis of genetic in-
fluence on delirium amongst the 73 studies included in this review. 
Methods involved PCR or genotype analysis. 
3.12. Cortisol 
Eleven studies (Supplementary Table 13) evaluated association be-
tween cortisol and delirium, with eight indicating a significant positive 
association between elevated plasma cortisol levels and delirium. The 
results of the remaining three studies did not support this observation. 
Cortisol was assessed alone in four studies, and alongside inflammatory 
markers in the remainder [20,21,34,38,48,54,85]. 
Results varied between studies that had adjusted for comorbidities 
and those that did not. All six studies evaluating cortisol as a marker of 
pure delirium indicated a positive association between cortisol and 
delirium [21,48,54,81,82,84], while amongst those adjusting for 
comorbidities three studies demonstrated a positive association 
[20,38,83], while two did not [34,85]. Kazmeirzski et al. [83] found pre- 
and post-operative cortisol significantly elevated in post-operative 
delirious patients compared to non-delirious controls. The significance 
of elevated cortisol remained after controlling for cognitive impairment, 
but not major depressive disorder. Elevation of cortisol in acute states of 
inflammation or trauma may be significant here and is extrapolated in 
the discussion section below. For example, Sun et al. [38] showed 
elevated levels of all inflammatory biomarkers tested in the study, 
including cortisol, in their patients and found no difference between 
patients with and without delirium. Similarly, van den Boogard et al. 
[54] noted that, as well as cortisol, elevated S100B and IL-8 were 
associated with delirium. 
Surgical settings, either cardiac or orthopaedic surgery, were more 
common amongst the studies assessing cortisol in delirium, accounting 
for eight of eleven studies, of which five showed an association between 
cortisol and delirium. This included elevations in cortisol during 
delirium [21,81], in the postoperative period [20,82], or both the pre- 
operative and post-operative period [83]. All three studies in medical 
setting reported positive associations between cortisol and delirium. In 
the main, serum samples were assayed using ELISA and CLIA with the 
exception of one study that analyzed additional CSF samples [81]. 
3.13. Estradiol 
One study investigated the relationship between estradiol (E2) and 
delirium in acute medically ill women [86](Supplementary Table 14). 
The study adjusted for covariates including age, pre-existing cognitive 
dysfunction and depression. Serum E2 was significantly elevated in 
delirious patients. 
3.14. TNF-alpha 
Nine studies investigated the relationship between either TNF-alpha 
or its related receptor, Soluble Tumour Necrosis Factor Receptor 
(STNFR), and delirium with five indicating a positive association, one 
showing no association and three returning marker levels below a suf-
ficient threshold for meaningful analysis (Supplementary Table 15). In 
all cases, TNF-alpha was assessed as one of a panel of inflammatory 
markers. 
Six studies measured TNF-alpha or its receptor in the setting of pure 
delirium. Four reported an association between pure delirium and 
elevated TNF-alpha in either surgical [39] or medical patients 
[49,55,59]. Of note, two of these four studies [55,59] measured the 
STNFR. One study [43] stated no association between TNF-alpha levels 
in blood samples between medical patient groups with and without 
delirium. One study [41] reported measurements below the detectable 
level unsuitable for analysis. Three studies measured TNF-alpha in the 
setting of delirium adjusting for comorbidities, all of which involved 
surgical patients. Only one of these [58] had viable samples and showed 
a positive association. Two [36,42] returned measurements below the 
detectable level unsuitable for analysis. 
Studies investigating pure delirium made up the larger part of the 
group, accounting for six of nine studies. There was no pattern of posi-
tive results when comparing medical vs. surgical settings. Only one of 
three studies returned a viable sample in studies adjusting for comor-
bidities, precluding meaningful analysis of the effect of comorbidities on 
studies assessing associations between TNF-alpha and delirium. Studies 
assessing TNF alpha mainly used serum [34,39,41,42,49,58,59], 
although one used whole blood [43] and one used CSF [36]. 
4. Discussion 
This is a comprehensive systematic review. Although not a meta- 
analysis, arising from the review, we determine that there is insuffi-
cient evidence to support the use of any single biomarker as a sole risk or 
disease marker of delirium. However, there are biomarkers with sig-
nificance in some clinical settings, and these may provide direction for 
future studies and more in-depth analysis. This statement is made while 
cognizant of the fact that the underlying etiology of delirium is multi-
faceted, with potential pathologies ranging from peripheral inflamma-
tion, stress, or trauma to systems within the hypothalamic-pituitary- 
adrenal axis. Furthermore, challenges in ascertaining specific bio-
markers' associations with delirium were evident, due to the heteroge-
neity of studies. More specifically, it was impossible to quantify strength 
of identified associations, positive or negative, due to the differences 
evident in methodologies, diverse patient populations, criteria for 
delirium diagnosis, involvement of confounding comorbidities (e.g., 
dementia) 
[16–19,21,23–25,27,30,34,42–53,57–59,67,68,70,71,75–77,80,81, 
84–86,89,93], and analytical approaches adopted. Further complexity is 
added by the non-specificity of many of the investigated biomarkers. 
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Trauma relating to surgery, for example, is associated with alteration in 
many of the pro-inflammatory markers that are posited as having links 
to delirium, as further discussed in Hirsch et al. [36]. Similarly, many 
inflammatory markers are elevated in co-existing neuropsychiatric 
conditions. Despite this, appraisal of the papers identified the themes 
outlined below. 
4.1. Disturbances in neurotransmitter pathways 
The outcomes of several studies lend support to the hypothesis that 
delirium is attributable to, or at least contributed to by, disturbances in 
neurotransmitter pathways. Serotonin, dopamine and other neuro-
transmitters as well as neurotransmitter-like compounds such as the 
hormone melatonin, play roles in effective cognition, learning, memory, 
attention and sleep wake cycles. The neurotransmitter hypothesis sug-
gests that imbalances in the levels of any neurotransmitter(s) or 
disruption of their mechanistic pathway impact pathogenesis of 
delirium [8]. Tryptophan, phenylalanine and tyrosine are all precursors 
to serotonin, dopamine and noradrenaline, respectively [87], and, 
therefore, may also be implicated. 
In this context, cholinergic deficiency has been proposed as linked 
directly with the pathogenesis of delirium [11]. Adequate acetylcholine 
levels are required for regulation of sleep, memory, cognition, learning 
and selective attention [88]. An impairment of cholinergic activity 
could, thereby, plausibly lead to dementia and delirium. Three studies 
measuring the link between SAA and delirium found no associations in 
either medical or surgical settings [16 18 19]. This is in contrast to the 
finding of Flacker et al. [89] and Mussi et al. [90] who showed positive 
correlations between SAA and delirium. However, methods of detection 
were different and pre-existing cognitive dysfunction and age, well- 
known confounders of SAA activity and delirium, were not adjusted 
for in the findings. Overall, it is noteworthy that SAA is not necessarily 
aligned with central cholinergic function, which may be most relevant to 
delirium. 
Cholinergic activity has also been linked to anti-inflammatory 
pathways through inhibition of pro-inflammatory cytokines [8,91]. A 
loss of cholinergic activity may lead to an increased inflammatory 
response, possibly contributing to delirium. Studies by Zhao et al. [15] 
and Cerejeira et al. [22] support a putative mechanism, demonstrating 
low plasma cholinesterase activity of AchE and BuChe prior to surgery in 
patients who developed post-operative delirium subsequently. In the 
Cerejeira et al. papers, a correlation between low cholinesterase activity 
and elevated levels of CRP and IL-6 was also present. This evidence 
contradicts the proposed mechanism that relies on cholinergic defi-
ciency leading to inflammation. The studies do, however, state that 
pharmaceutical drugs interacting with cholinergic activity were not 
taken into account, which may have affected the outcomes. 
Central serotonin deficiency has also been linked to the development 
of a delirious state via tryptophan depletion [92]. Reports have shown 
increased or decreased levels of tryptophan associated with delirium, 
either through direct measurement of the amino acid or its ratio to other 
large amino acids. These results are similar in both medical and surgical 
settings, both in pure-delirium studies and in those assessing delirium 
with comorbidities. While there is evidence to substantiate a tryptophan 
deletion theory, a randomized trial by Robinson et al. [93], in which 
patients undergoing hip surgery were administered supplementary 
tryptophan, did not result in any reduction of post-operative delirium 
compared to controls. 
Dopamine plays a role in control of the features characterizing 
delirium including changes in movement, cognition, attention and 
memory [94,95]. Accordingly, dopamine excess has been hypothesized 
to contribute to pathophysiology of delirium [23,94,95]. Most studies of 
phenylalanine, a precursor of dopamine, as a possible biomarker of 
delirium observed elevated levels in patients with delirium compared to 
controls. Osse et al. [24] showed an association between delirium and a 
metabolite of dopamine (HVA),while Ramirez et al. [25] and Egberts 
et al. [23] did not. 
Melatonin, a hormone produced by the pineal gland, affects circa-
dian rhythms including the regulation of sleep-wake cycles [31]. One 
feature of delirium is the disturbed sleep-wake cycle and it is postulated 
that disturbed melatonin rhythms could be involved in delirium [96]. 
While all studies reviewed showed disturbances in melatonin concen-
trations during various stages of delirium, further research is needed to 
clarify the role of melatonin in delirium. Specifically, due to the low 
numbers of participants in eligible studies examining melatonin, larger 
group studies for this biomarker would be welcome. 
4.2. Activation of pro-inflammatory cytokines resulting in the breakdown 
of the blood brain barrier 
Several studies lend partial support to this hypothesis, albeit results 
are conflicting. The neuroinflammatory theory of delirium postulates 
that peripheral inflammation secondary to infections, surgery or trauma 
induces the activation of the pro-inflammatory cascade and suppression 
of anti-inflammatory markers [88]. The pro-inflammatory molecules 
cross the blood brain barrier (BBB), causing insult to the central nervous 
system, resulting in the neurobehavioral and cognitive symptoms asso-
ciated with delirium [88]. 
IL-6 is one of the most studied cytokines with regard to its potential 
as a marker of delirium. Not all studies demonstrated an association 
between elevated levels of IL-6 and delirium, or the risk of developing 
delirium. Studies that demonstrated an association between high levels 
of pre-operative IL-6 and delirium [35,37,39,41] suggest that early 
manifestation of systemic inflammation leads to the onset of delirium. 
Infection, cognitive dysfunction and age have been shown to be inde-
pendently associated with IL-6 [97–99], and not all of the studies 
adjusted for these variables, which may have influenced the significance 
and extent of association. 
Similarly, studies of delirium with comorbidities had conflicting 
outcomes. There are many sources of heterogeneity between the studies 
investigating IL-6 as a marker including methods of IL-6 analysis, patient 
settings, and adjustment for known variables. However, because IL-6 is 
associated with age, infection, inflammation, cognitive dysfunction and 
many other systemic processes, using IL-6 as a potential marker will 
remain challenging. 
Indeed, many of the studies investigated other pro-inflammatory 
cytokines and potential biomarkers of delirium. No consistency or 
conclusive marker was established. Research has identified relationships 
between levels of IL-8, cognition and age [100,101]. Cognition and age 
are both independent risk factors of delirium, suggesting a role for IL-8 
in its development. However, the outcomes of our review highlighted 
conflicting data and opinions. In relation to both IL-6 and IL-8, this re-
view supports the view that they continue to be measured alongside 
other inflammatory markers and that researchers work to adjust for 
inflammation. Doing so may help clarify the interaction between 
delirium and inflammation, and perhaps shed light on pathogenesis. 
In addition to IL-1B being a pro-inflammatory cytokine, linking it to 
the inflammatory theory of delirium, it is further recognized as inter-
fering with cholinergic signaling, a pathway thought to be involved in 
the pathogenesis of delirium [102]. IL-1B was assessed in four studies 
with conflicting results. Notably, animal research has proven that 
modulation of IL-1B through lipopolysaccharide(LPS) receptor blockade 
improves cognitive dysfunction [102]. It is not surprising then that 
studies on delirium with comorbidities [22,56] adjusted for pre-existing 
cognitive dysfunction, found no obvious difference in results. Overall, 
evidence does not support the use of IL-1 as a specific biomarker of 
delirium. 
IL-2 is particularly important in T- cell activation [58]. It has also 
been shown to block acetylcholine stimulation in the CNS and to stim-
ulate dopamine, two processes thought to be involved in the patho-
physiology of delirium. Like the other cytokines, IL-2 results conflicted. 
However, Kazmierski et al. [58] showed independent associations 
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between levels of IL-2 and pre-existing cognitive dysfunction that 
remained significant after adjusting for comorbidities. 
CRP is a circulating acute phase reactant and a common marker for 
infection and inflammation. Similar etiologies in delirium therefore 
suggest a role for CRP in the pathophysiology of delirium [45]. Evidence 
suggest that post-operative delirium, in which the mechanism of 
inflammation is known, CRP might play a role as a risk or disease marker 
of delirium [67] due partially to it being readily and easily measurable. 
However, as it is associated with many other inflammatory pathways, it 
is less likely to be specific to delirium. 
IGF-1 is a neuroprotective cytokine with a role in promoting neu-
rogenesis, proliferation, differentiation and synaptogenesis [103]. It is 
also thought to inhibit cytotoxic cytokines such as IL-6, IL-8 and IL-1 
[104]. Low levels of IGF-1 are, therefore, thought to be associated 
with a loss or decline of its neuroprotective characteristics [70]. This 
suggested pathophysiology could lead to increased vulnerability of the 
brain to insults resulting in neurological injury and delirium. In addi-
tion, loss of inhibition of the cytotoxic cytokines leads to increased pro- 
inflammatory cytokines. In actuality, studies show inconsistencies in the 
association between levels of IGF-1 and delirium. Some indicated low 
levels of IGF-1 associated with delirium, which is in keeping with the 
neuroinflammatory hypothesis but, when separated into patient set-
tings, there was no relationship between pre-operative and post-
operative levels of IGF-1 and delirium, suggesting a role for IGF-1 in the 
medical setting only. In the medical setting, all but one study showed a 
positive association between low levels of IGF-1 and delirium onset. 
Therefore, IGF-1 may play a role as a diagnostic marker in acute 
medically ill patients but have less significance in post-operative 
delirium.IGF-1 has also been linked to the pathophysiology of Alz-
heimer's Dementia (AD) [105,106]. Lower levels of IGF-1 in AD lead to 
reduced clearance of amyloid beta plaques enhancing AD development. 
Studies of delirium with comorbidities, however, did not show consis-
tency in outcomes. 
S100–B, a calcium binding protein, is expressed mainly by astro-
cytes and is elevated after disturbances in the integrity of astrocytes 
[107]. S100–B plays a role in axonal growth and neuronal regeneration 
[86]. Elevated levels have been linked to traumatic brain injury, stroke 
and neuro-intensive care patients. Activation of astrocytes via systemic 
inflammation is thought to lead to raised levels of S100–B in the pe-
ripheral blood via increased permeability of the blood brain barrier 
[88]. In our review, results were found to be inconsistent and conflict-
ing. One notable area of concordance was that all studies involving a 
post-operative setting found a significant positive association between 
S100B and delirium. Notably, the outcomes of one study [75] suggested 
that this marker may have a role in studying delirium over extended 
durations. 
Apolipoprotein E4 allele (APOE) is a polymorphic protein that exists 
as three major isoforms, e2, e3, and e4 [108]. It is involved in the lipid 
transport and acetylcholine synthesis important in the repair, growth 
and maintenance of myelin and neuronal membranes during develop-
ment or post injury [108].The e4 allele has been associated with earlier 
onset of AD [109], poor outcome post closed head injury and intracra-
nial injury [110]. It has been hypothesized that patients with the e4 
allele have a genetic predisposition to post-operative delirium after 
surgery. In addition, due to well-known relationship between delirium 
and dementia, it has been postulated that APOE4 contributes to the 
pathophysiology of delirium. Although there is suggested link between 
APOE and dementia, only one study involved pre-existing cognitive 
dysfunction as comorbidity [53]. With the known association between 
Alzheimer's and APOE, as well as its involvement in other possible 
neuropsychiatric conditions, APOE is a less than specific marker for 
delirium and researchers may consider evaluating other genes, as dis-
cussed under ‘implications for future study’ below. 
TNF-alpha is a pleiotropic cytokine that signals several pathways 
relating to homeostasis and the pathogenesis of disease including 
inflammation, apoptosis and necrosis [111]. There is no consensus on 
the full extent of the role played by TNF-alpha and its receptor in 
inflammation, including in the CNS [112]. Despite this, studies have 
indicated a strong association of this marker with cognitive decline in 
the setting of Alzheimer's Disease [113], albeit that results have been 
equivocal [39] regarding an association with delirium. While some 
studies included in this review showed a positive association between 
TNF-alpha and its related receptor to delirium, one third of studies 
measuring these markers stated results that either did not reach signif-
icance or detected insufficient levels to determine a relationship be-
tween the marker and delirium. Given the strong associations with 
cognitive decline and the proportion of studies unable to reach a 
meaningful conclusion, this marker warrants further investigation. 
Wider biochemical research into its role in signaling pathways may help 
to elucidate its function in the CNS, shedding further light on the 
pathogenesis of delirium. Due to its association with inflammation, 
future studies may clarify its role in delirium further by adjusting for 
covariates, including inflammation, as is the case in van den Boogaard 
et al. [54] 
4.3. Disruption of the hypothalamic-pituitary-axis in reaction to acute 
stress 
The hypothalamic-pituitary-axis forms a response to stressful or 
traumatic insults to the body. Cortisol is the main effector of this process 
and rises as a result of these insults [114]. Elevated levels of cortisol 
affect the hippocampus and frontal lobe triggering neuropsychiatric 
characteristics and cognitive dysfunction seen in delirium [114,115]. 
Elevated levels of cortisol are not only associated with delirium but 
dementia, age and cognitive dysfunction [115]. Findings from this sys-
temic review determine conflicting support for the hypothesis that 
delirium is associated with elevated cortisol levels. It should be noted, 
however, that all studies of pure delirium found an association between 
elevated levels of cortisol and delirium, identifying the connection be-
tween cortisol and pure delirium as an area for further study. The dif-
ference in positive results between studies of cortisol in this review that 
adjusted for comorbidities, and those that did not, suggest that further 
research into this marker may benefit from adjustment for confounders. 
A 2015 study by Avila-Funes et al. [86] has found a link between 
elevated levels of estradiol and delirium in women. This result remained 
significant after adjusting for covariates including age, pre-existing 
cognitive dysfunction and depression. Estrogen has been implicated in 
cognitive dysfunction [116] and, therefore, thought to have a role in 
delirium. This warrants further investigation. 
4.4. Limitations 
The results of this systematic review highlight the lack of published 
studies with comparable methodologies examining biomarkers in 
delirium; at least up to June 2019. We did not attempt meta-analysis as it 
was impossible to quantify strength of identified associations, positive or 
negative, due to the differences evident in methodologies, diverse pa-
tient populations, criteria for delirium diagnosis, involvement of con-
founding comorbidities. Our review was limited to studies published in 
the English language. No unpublished literature was obtained. Although 
studies were retrieved through database searches and the citation lists of 
relevant articles reviewed for eligibility, it is possible that relevant ar-
ticles may have been missed. However, the authors are confident that no 
significant articles have been missed. Publications reporting association 
with BDNF (brain-derived neurotrophic factor) (e.g.,[117,118]) were 
not included in this review as all trials of BDNF delivered into the CNS, 
even for special reasoning or memory, have failed (as of February 2021). 
Strengths of this review reflect the inclusion of the most-recent literature 
available in this field of study (up to June 2019) and assessment of 
delirium with standardized diagnostic tools. 
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5. Implications for future research 
In brief, this review highlights the need for more focused research on 
this topic. The pathophysiology of delirium remains unclear. Future 
research should ensure use of standardized clinical criteria and assess-
ment tools for delirium, adjust appropriately for comorbidities as well as 
consider generalizable populations, prospective designs and appropriate 
sample sizes. Analysis of delirium could also include delirium subtype. 
With regard to healthcare setting, these studies suggest there may be 
value in continuing to differentiate between medical and surgical pa-
tients when evaluating the efficacy of delirium biomarkers, and suggest 
a possible role for biomarkers in the prediction of post-operative 
delirium. It is, perhaps, in this setting that most immediate progress 
can be made. More specifically, effects of withdrawal from significant 
use of opioids (and epidural) in surgical procedures can impair cognition 
and be interpreted as delirium. Advances have been made recently in 
developing robust animal models relevant to surgery and, indeed, or-
thopaedic surgery in particular [119–122]. These have considerable 
potential in clarifying what appear to be tightly interwoven correlations 
between the varying biomarkers described here; for example, delirium 
and inflammatory markers such as CRP. Our review also concludes that 
while many studies attempted to establish the time-course of delirium, 
few involved long term follow up and only one [89] involved a long term 
care facility. Expansion of research into settings outside acute medical 
and surgical settings may be beneficial to understanding the time-course 
and patterns of delirium. [14] 
Greater standardization of sampling and inclusion of other diag-
nostic modalities may benefit future research. To the authors' knowl-
edge, this is one of two systematic reviews to examine biomarkers in 
delirium, and the only review to appraise samples other than CSF. Given 
that non-CNS sampling has been shown to yield information about the 
brain that differs from that gleaned from CSF [123], further studies 
involving peripheral, as well as CSF samples, may help to shed light on 
the pathophysiology of delirium. This may prove critical in under-
standing the interaction between the systemic and CNS inflammatory 
components, and the impact of delirium on the body as a whole. The 
diversity of reported sampling, including whole blood, serum, plasma 
and CSF in studies reviewed here is, therefore, welcome. It is noteworthy 
that of the 73 included studies, only three [18,19,21] combined bio-
markers with other diagnostic modalities such as EEG. With current 
biomarker associations unclear, future research may benefit from 
combining biomarkers with diagnostic modalities such as EEG, which 
has proven benefit in diagnosis of delirium [124]. Epigenetic analysis 
remains an interesting proposition in potentially understanding and 
detecting delirium in clinical practice. More specifically, there has been 
elegant work published describing the emerging potential influence of 
DNA methylation on expression of genes encoding for pro-inflammatory 
cytokines in aging and delirious patients [125,126]. Association of DNA 
methylation with cholinergic synapse has also been suggested [127]. 
These warrant further focus. Future studies may also choose to include 
genetic analysis as this review found these to be limited, feature in only 
six studies, amongst which APOE was the only gene assessed. Stoicea 
et al. have described several genes known to be associated with delirium 
and may provide a helpful summary for researchers [128]. 
Overall, future research should be informed by, but healthily scep-
tical of, previous studies on biomarkers and factors demonstrated to 
have an association with delirium. Delirium is a complex multifaceted 
syndrome such that the relationship between particular elements of the 
syndrome (cognitive vs neuropsychiatric) and alterations in biomarkers 
or their levels warrant study. This may eventually illuminate our un-
derstanding of the pathophysiology of the various components of 
delirium. It is likely that, in time, the correlations described in this re-
view will be clarified, and either confirmed or discarded, as systems 
biology approaches elucidate the pathways that involve multiple, 
interdependent biomarkers that most likely influence the complex 
mechanisms mediating delirium. Equally, this can be applied to 
exploring the genesis of different clinical presentations (e.g., motor 
subtypes) of delirium. In this context, however, confidence in any po-
tential test arising from such a complex molecular milieu will likely 
require extensive and credible meta-analysis of proposed sensitivities, 
specificities and threshold values in a rigorous manner analogous to that 
proposed by Campbell et al. [129]. 
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